---
layout: default
title: Apis Mellifera Arctium Lappa Root Arctostaphylos U
parent: Model Prediction Only (L5)
nav_order: 382
evidence_level: L5
indication_count: 0
---

# Apis Mellifera Arctium Lappa Root Arctostaphylos U
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **0** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Multi-Component Herbal/Homeopathic Formula: Drug Repurposing Assessment Execution Not Possible

## One-Sentence Summary

This candidate medicine is a multi-component formulation containing 20 botanical and homeopathic ingredients (including Apis Mellifera, Uva-Ursi, Saw Palmetto, Cantharis, etc.), traditionally used for urinary tract-related indications. The TxGNN model generated no repurposing predictions because this formulation has no corresponding DrugBank ID and cannot be mapped to a single molecular entity in the knowledge graph. Currently, no predicted indications, clinical trials, or literature are available for evaluation; the overall assessment work encounters a fundamental data gap.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | No data (no regulatory approval in any country) |
| Predicted New Indication | No prediction (TxGNN unable to process) |
| TxGNN Prediction Score | N/A |
| Evidence Level | Unable to rate (below L5) |
| Market Status | Not Marketed |
| Number of Licenses | 0 |
| Recommended Decision | **Hold** |

---

## Why This Formula Could Not Be Evaluated

This formulation is composed of 20 ingredients below, most of which are common raw materials in homeopathic or herbal preparations:

| # | Ingredient | Traditional Use |
|---|-----------|-----------------|
| 1 | Apis Mellifera (honeybee) | Edema, urinary tract inflammation (homeopathic) |
| 2 | Arctium Lappa Root (burdock root) | Diuretic, lymphatic, skin |
| 3 | Arctostaphylos Uva-Ursi Leaf (bearberry leaf) | Urinary tract infection (UTI), diuretic |
| 4 | Berberis Vulgaris Root Bark (barberry root bark) | Kidney stones, urinary tract (homeopathic) |
| 5 | Bryonia Alba Root (white bryony root) | Joints, respiratory tract (homeopathic) |
| 6 | Chondrodendron Tomentosum Root (curare plant) | Contains tubocurarine precursor, muscle relaxant |
| 7 | Cinchona Officinalis Bark (cinchona bark) | Malaria, fever reduction (quinine source) |
| 8 | Echinacea (purple coneflower) | Immune support |
| 9 | Equisetum Hyemale (horsetail) | Diuretic, urinary tract |
| 10 | Ferrosoferric Phosphate (ferric phosphate) | Early inflammation (Ferrum phos., homeopathic) |
| 11 | Gelsemium Sempervirens Root (Carolina jasmine root) | Neuralgia, fever (homeopathic; toxic) |
| 12 | Goldenseal | Antimicrobial, gastrointestinal, mucosal |
| 13 | Juniper Berry | Diuretic, urinary tract antiseptic |
| 14 | Lytta Vesicatoria (Spanish fly, Cantharis) | Cystitis, urethritis (homeopathic); raw substance is toxic |
| 15 | Phosphorus | Liver, nervous system (homeopathic) |
| 16 | Plantago Major (plantain) | Anti-inflammatory, urinary tract |
| 17 | Pulsatilla Vulgaris (pasque flower) | Urinary tract, gynecological (homeopathic) |
| 18 | Saw Palmetto | Benign prostatic hyperplasia (BPH) |
| 19 | Solidago Virgaurea Flowering Top (goldenrod) | Urinary tract anti-inflammatory, diuretic |
| 20 | Turpentine (pine oil) | Urinary tract (historical use); irritant |

**The core reasons why assessment could not be executed are as follows:**

1. **No DrugBank ID**: The TxGNN knowledge graph uses single molecules (small molecules) as nodes. This formulation is a multi-component complex and cannot be mapped to any knowledge graph node, causing the model to fail completely at prediction generation.

2. **Homeopathic specificity**: Some ingredients (e.g., Phosphorus, Cantharis, Pulsatilla) are used at extremely low potencies in homeopathy, and their mechanisms of action are incompatible with the modern pharmacological framework, making them difficult to incorporate into TxGNN's evidence-based evaluation system.

3. **Raw substance toxicity issues**: Both Lytta Vesicatoria (containing cantharidin) and Gelsemium sempervirens (containing gelsemine) raw substances possess significant toxicity; if used other than as homeopathic potencies, safety assessment requires special care.

4. **No existing approval records**: No regulatory authorization found in any country, and no FDA/EMA/TFDA approval record exists, making it impossible to use as a regulatory baseline.

---

## US Market Information

This formulation has not received drug approval in the United States (FDA) or Taiwan (TFDA), nor is there any NDA/NHI registration record.

> Query Date: 2026-03-24 | Query Result: 0 authorization records

---

## Safety Considerations

Please refer to the individual package inserts or safety information for each ingredient. The following raw substance toxicities require special attention:

- **Lytta Vesicatoria (Cantharis)**: Raw substance contains cantharidin, exhibiting renal toxicity and severe mucosal irritation; internal use prohibited unless in homeopathic potency
- **Gelsemium sempervirens**: Contains gelsemine, exhibiting neurotoxicity; toxic doses can result in respiratory depression
- **Chondrodendron tomentosum**: Contains D-tubocurarine (curare) precursor; raw substance is a neuromuscular blocking agent

Drug-drug interaction (DDI) query: Standardized data not found (this multi-component formulation exceeds the scope of standard DDI databases).

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
This formulation is a homeopathic/herbal complex for which the TxGNN model cannot generate repurposing predictions. Furthermore, existing safety and regulatory data are completely lacking, providing no basis for any repurposing assessment.

**To proceed, the following is needed:**

- **Data restructuring**: If individual component evaluation is desired, the formulation must be decomposed into single active components (e.g., separately evaluate berberine from Berberis, quinine from Cinchona, β-sitosterol from Saw Palmetto), and each queried for its DrugBank ID
- **Regulatory clarification**: Determine the regulatory classification of this formulation in the target market (United States/Taiwan)—whether it is an OTC drug, dietary supplement, or homeopathic remedy—to decide on applicable evaluation standards
- **Safety data supplementation**: For ingredients containing toxic raw substances (Cantharis, Gelsemium), obtain complete documentation on potency levels and safety
- **Manufacturer labeling query**: Obtain the complete package insert from the manufacturer to confirm actual indication claims and ingredient ratios

> ⚠️ **Note**: This report is for research reference only and does not constitute medical advice. Drug repurposing candidates require clinical validation before application.

## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

